Company Profiles

driven by the PitchBook Platform

Abpro

Abpro
2007 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Series D LATEST DEAL TYPE (In Progress)
$10M LATEST DEAL AMOUNT
$29.4M TOTAL AMOUNT RAISED
Description

Developer of therapeutic antibody technology intended to target human disease. The company's DiversImmuneTM platform leverages synthetic biology and immunology to generate therapeutic antibodies against novel and challenging targets, enabling biotechnology and pharmaceutical companies to develop many therapeutic antibodies against traditionally difficult targets.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Other Healthcare Services
Primary Office
65 Cummings Park Drive
Woburn, MA 01801
United States

+1 (800) 396-5890
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Abpro’s full profile, request a free trial.

Abpro Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 31-Mar-2017 $10M $29.4M 00000 In Progress Clinical Trials - General
3. Corporate (Series C) 06-Apr-2016 000.00 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 11-Aug-2015 $5.2M $7M $41.6M Completed Generating Revenue
1. Angel (individual) 20-Sep-2007 $1.8M $1.8M $10M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Abpro Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 0,000,000 00.000000 000.0 000.0 00 000.0 0.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 2,500,000 $0.001000 $2.08 $2.08 1x $2.08 11.49%
Series A 34,372 $0.001000 $67.51 $67.51 1x $0.68 15.8%
To view this company’s complete Cap Table request access »

Abpro Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AngelVest Group Angel Group Minority 000 0000 000000 0
Essex Bio-technology Corporation Minority 000 0000 000000 0
Individual Investor Angel (individual) Minority 000 0000 000000 0

Abpro Executive Team (5)

Name Title Board
Seat
Contact
Info
Ian Chan Co-Founder, Chief Executive Officer & Chairman
Adam Mostafa Chief Financial Officer
Gavin MacBeath Ph.D Chief Scientific Officer
Jessie Wong Ph.D Director, Business Development
Eugene Chan MD Co-Founder, Chief Scientific Officer, Scientific Advisor & Vice Chairman

Abpro Board Members (7)

Name Representing Role Since Contact
Info
Benjamin Ha Abpro Board Member 000 0000
Bob Langer Abpro Board Member 000 0000
Eugene Chan MD Self Co-Founder, Chief Scientific Officer, Scientific Advisor & Vice Chairman 000 0000
Frank Ye Abpro Board Member 000 0000
Ian Chan Abpro Co-Founder, Chief Executive Officer & Chairman 000 0000

1 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »